X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (143) 143
oncology (133) 133
index medicus (109) 109
female (85) 85
lung neoplasms - drug therapy (83) 83
carcinoma, non-small-cell lung - drug therapy (77) 77
male (72) 72
middle aged (72) 72
aged (70) 70
chemotherapy (64) 64
adult (55) 55
lung cancer (55) 55
lung neoplasms - pathology (55) 55
lung neoplasms - genetics (46) 46
carcinoma, non-small-cell lung - genetics (43) 43
cancer (41) 41
lung cancer, non-small cell (41) 41
carcinoma, non-small-cell lung - pathology (40) 40
antineoplastic combined chemotherapy protocols - therapeutic use (36) 36
treatment outcome (36) 36
respiratory system (35) 35
antineoplastic agents - therapeutic use (31) 31
aged, 80 and over (30) 30
mutation (29) 29
survival (29) 29
neoplasm staging (28) 28
open-label (28) 28
disease-free survival (26) 26
care and treatment (25) 25
gefitinib (25) 25
lung neoplasms - mortality (25) 25
hematology, oncology and palliative medicine (23) 23
nsclc (23) 23
tumors (23) 23
lung neoplasms - therapy (22) 22
carcinoma, non-small-cell lung - mortality (21) 21
prognosis (21) 21
cisplatin (20) 20
docetaxel (20) 20
adenocarcinoma (19) 19
erlotinib (19) 19
patients (19) 19
egfr (18) 18
phase-iii trial (18) 18
protein kinase inhibitors - therapeutic use (18) 18
survival analysis (18) 18
therapy (18) 18
antineoplastic combined chemotherapy protocols - adverse effects (17) 17
lung neoplasms - diagnosis (17) 17
pulmonary/respiratory (17) 17
acquired-resistance (16) 16
cancer therapies (16) 16
carcinoma, non-small-cell lung - therapy (16) 16
cisplatin - administration & dosage (16) 16
kaplan-meier estimate (16) 16
non-small cell lung cancer (16) 16
non-small cell lung carcinoma (16) 16
safety (16) 16
biomarkers (15) 15
carcinoma, non-small-cell lung - diagnosis (15) 15
crizotinib (15) 15
drug administration schedule (15) 15
growth-factor receptor (15) 15
metastasis (15) 15
non-small-cell lung cancer (15) 15
analysis (13) 13
antineoplastic agents - adverse effects (13) 13
cell lung-cancer (13) 13
clinical trials (13) 13
immunotherapy (13) 13
medicine & public health (13) 13
quinazolines - therapeutic use (13) 13
receptor, epidermal growth factor - antagonists & inhibitors (13) 13
trial (13) 13
carboplatin - administration & dosage (12) 12
clinical trials as topic (12) 12
disease progression (12) 12
epidermal growth factor (12) 12
mutations (12) 12
radiotherapy (12) 12
receptor, epidermal growth factor - genetics (12) 12
respiratory tract diseases (12) 12
animals (11) 11
carcinoma (11) 11
epidermal growth factor receptors (11) 11
multicenter (11) 11
nivolumab (11) 11
pembrolizumab (11) 11
protein kinase inhibitors - adverse effects (11) 11
research (11) 11
survival rate (11) 11
tyrosine (11) 11
abridged index medicus (10) 10
apoptosis (10) 10
article (10) 10
carboplatin (10) 10
combined modality therapy (10) 10
erlotinib hydrochloride (10) 10
europe (10) 10
gene expression (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10027, pp. 1540 - 1550
Summary Background Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for... 
Internal Medicine | CRITERIA | MEDICINE, GENERAL & INTERNAL | ANTI-PD-L1 ANTIBODY | THERAPY | NSCLC | IMMUNOTHERAPY | PD-L1 | BLOCKADE | NIVOLUMAB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Molecular Targeted Therapy | Patient Selection | Taxoids - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Agents - adverse effects | Adult | Female | Taxoids - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Lung Neoplasms - chemistry | Docetaxel | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Taxoids - administration & dosage | Aged | B7-H1 Antigen - analysis | Carcinoma, Non-Small-Cell Lung - drug therapy | Antimitotic agents | Medical colleges | Lung cancer, Non-small cell | Antineoplastic agents | Analysis | Chemotherapy | Biopsy | Genes | Lung cancer | Clinical trials | Oncology | Mutation | Tumors | Slopes | Cell survival | Medical treatment | Medical services | FDA approval | Survival | Patients | Medical centres | Pembrolizumab | Randomization | Interactive systems | Immunotherapy | Risk assessment | PD-L1 protein | Biomarkers
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 897 - 907
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 874 - 886
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 4, pp. 452 - 463
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2015, Volume 372, Issue 21, pp. 2018 - 2028
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 22, pp. 2078 - 2092
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 212 - 223
Summary Background MUC1 is a tumour-associated antigen expressed by many solid tumours, including non-small-cell lung cancer. TG4010 is a modified vaccinia... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | MVA-MUC1-IL2 | PROSTATE-CANCER | VACCINE | Predictive Value of Tests | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Fatigue - etiology | Male | Cisplatin - administration & dosage | Antigens, CD - analysis | Antigens, Differentiation, T-Lymphocyte - analysis | Neutropenia - etiology | Cancer Vaccines - therapeutic use | Receptors, IgG - analysis | Mucin-1 - analysis | Lectins, C-Type - analysis | Female | Paclitaxel - administration & dosage | Lymphocytes - chemistry | Anemia - etiology | Bevacizumab - administration & dosage | Double-Blind Method | Lung Neoplasms - chemistry | Lymphocyte Activation | CD56 Antigen - analysis | Deoxycytidine - administration & dosage | Erlotinib Hydrochloride - administration & dosage | Carboplatin - administration & dosage | Cancer Vaccines - adverse effects | Lung Neoplasms - therapy | Immunotherapy - adverse effects | Biomarkers, Tumor - blood | Disease-Free Survival | Carcinoma, Non-Small-Cell Lung - therapy | Membrane Glycoproteins - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pemetrexed - administration & dosage | Aged | Membrane Glycoproteins - adverse effects | Deoxycytidine - analogs & derivatives | Antigens | Fc receptors | Hospitals | Interleukins | Immunotherapy | Mucins | Clinical trials | Product development | Lung cancer, Non-small cell | Analysis
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 25, pp. 2415 - 2426
Journal Article